Anne Wojcicki's nonprofit TTAM acquires 23andMe for $305 million, ending the gene-testing pioneer's bankruptcy saga. The deal still faces state regulators' objections over genetic data control.

Office of the Utah Attorney General and the Utah Department of Commerce’s Division of Consumer Protection are issuing a ...

A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe's co-founder and former chief executive, Anne Wojcicki.

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s nonprofit acquires 23andMe.

Illumina sees new pharma interest, even as its business suffers several hits from NIH funding and a DOJ settlement.

The genetic testing company filed for Chapter 11 bankruptcy on March 23. Then-CEO and co-founder Anne Wojcicki also stepped down from the company.

TTAM Research Institute, formed by 23andMe’s co-founder and former CEO Anne Wojcicki, is now the new owner of substantially all of 23andMe’s assets.